As the functional mechanism of wild-type p53 expression is known to be mediated by the activation of its primary effector target p21 – a cyclin-dependent kinase inhibitor (CDKi) (26), we sought to determine the p21 expression in colon cancer cells in response to OX treatment in the context of p53 status. The gene discussed is TP53; the disease is colonic neoplasm.